164 related articles for article (PubMed ID: 32147777)
41. Therapeutic innovations in endocrine diseases - part 3 : temozolomide and future therapeutics for aggressive pituitary tumors and carcinomas.
Lasolle H; Raverot G
Presse Med; 2016 Jun; 45(6 Pt 2):e211-6. PubMed ID: 27242211
[TBL] [Abstract][Full Text] [Related]
42. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
McCormack AI; McDonald KL; Gill AJ; Clark SJ; Burt MG; Campbell KA; Braund WJ; Little NS; Cook RJ; Grossman AB; Robinson BG; Clifton-Bligh RJ
Clin Endocrinol (Oxf); 2009 Aug; 71(2):226-33. PubMed ID: 19067722
[TBL] [Abstract][Full Text] [Related]
43. Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.
Aharon-Hananel G; Percik R; Badarna M; Uri I; Tirosh A
Endocrine; 2019 Aug; 65(2):393-398. PubMed ID: 31267325
[TBL] [Abstract][Full Text] [Related]
44. Temozolomide and unusual indications: review of literature.
Tatar Z; Thivat E; Planchat E; Gimbergues P; Gadea E; Abrial C; Durando X
Cancer Treat Rev; 2013 Apr; 39(2):125-35. PubMed ID: 22818211
[TBL] [Abstract][Full Text] [Related]
45. Treatment of pituitary carcinomas and atypical pituitary adenomas: a review.
Hirohata T; Ishii Y; Matsuno A
Neurol Med Chir (Tokyo); 2014; 54(12):966-73. PubMed ID: 25446382
[TBL] [Abstract][Full Text] [Related]
46. Whole brain radiotherapy with concurrent temozolomide in multifocal and/or multicentric newly diagnosed glioblastoma.
Lahmi L; Idbaih A; Rivin Del Campo E; Hoang-Xuan K; Mokhtari K; Sanson M; Canova CH; Carpentier A; Jacob J; Maingon P; Feuvret L
J Clin Neurosci; 2019 Oct; 68():39-44. PubMed ID: 31399318
[TBL] [Abstract][Full Text] [Related]
47. Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor.
Ceccato F; Lombardi G; Albiger N; Mazzai L; Pambuku A; Rolma G; Zagonel V; Scaroni C
Anticancer Drugs; 2019 Jun; 30(5):533-536. PubMed ID: 30986806
[TBL] [Abstract][Full Text] [Related]
48. Temozolomide: mechanisms of action, repair and resistance.
Zhang J; Stevens MF; Bradshaw TD
Curr Mol Pharmacol; 2012 Jan; 5(1):102-14. PubMed ID: 22122467
[TBL] [Abstract][Full Text] [Related]
49. Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma.
Fateh S; Schell TD; Gingrich R; Neves RI; Drabick JJ
Cancer Biol Ther; 2010 Dec; 10(11):1091-7. PubMed ID: 20930514
[TBL] [Abstract][Full Text] [Related]
50. DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.
Hirohata T; Asano K; Ogawa Y; Takano S; Amano K; Isozaki O; Iwai Y; Sakata K; Fukuhara N; Nishioka H; Yamada S; Fujio S; Arita K; Takano K; Tominaga A; Hizuka N; Ikeda H; Osamura RY; Tahara S; Ishii Y; Kawamata T; Shimatsu A; Teramoto A; Matsuno A
J Clin Endocrinol Metab; 2013 Mar; 98(3):1130-6. PubMed ID: 23365123
[TBL] [Abstract][Full Text] [Related]
51. Downregulation of hsa_circ_0000936 sensitizes resistant glioma cells to temozolomide by sponging miR-1294.
Hua L; Huang L; Zhang X; Feng H
J Biosci; 2020; 45():. PubMed ID: 32975228
[TBL] [Abstract][Full Text] [Related]
52. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
53. Association of temozolomide with progressive multifocal leukoencephalopathy: a disproportionality analysis integrated with network pharmacology.
Bhati V; Kumar A; Lather V; Sharma R; Pandita D
Expert Opin Drug Saf; 2024 May; 23(5):649-658. PubMed ID: 37915230
[TBL] [Abstract][Full Text] [Related]
54. Cdc20 overexpression is involved in temozolomide-resistant glioma cells with epithelial-mesenchymal transition.
Wang J; Zhou F; Li Y; Li Q; Wu Z; Yu L; Yuan F; Liu J; Tian Y; Cao Y; Zhao Y; Zheng Y
Cell Cycle; 2017; 16(24):2355-2365. PubMed ID: 29108461
[TBL] [Abstract][Full Text] [Related]
55. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
56. Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches.
Wu S; Calero-Pérez P; Arús C; Candiota AP
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233585
[TBL] [Abstract][Full Text] [Related]
57. Cedrol, a Sesquiterpene Alcohol, Enhances the Anticancer Efficacy of Temozolomide in Attenuating Drug Resistance via Regulation of the DNA Damage Response and MGMT Expression.
Chang KF; Huang XF; Chang JT; Huang YC; Lo WS; Hsiao CY; Tsai NM
J Nat Prod; 2020 Oct; 83(10):3021-3029. PubMed ID: 32960603
[TBL] [Abstract][Full Text] [Related]
58. Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma.
Kamiya-Matsuoka C; Cachia D; Waguespack SG; Crane CH; Mahajan A; Brown PD; Nam JY; McCutcheon IE; Penas-Prado M
Pituitary; 2016 Aug; 19(4):415-21. PubMed ID: 27106209
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.
Xia Q; Liu L; Li Y; Zhang P; Han D; Dong L
Cancer Invest; 2021 Sep; 39(8):627-644. PubMed ID: 34254870
[TBL] [Abstract][Full Text] [Related]
60. Bcl2-Expressing Quiescent Type B Neural Stem Cells in the Ventricular-Subventricular Zone Are Resistant to Concurrent Temozolomide/X-Irradiation.
Cameron BD; Traver G; Roland JT; Brockman AA; Dean D; Johnson L; Boyd K; Ihrie RA; Freeman ML
Stem Cells; 2019 Dec; 37(12):1629-1639. PubMed ID: 31430423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
